Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer.
von der Lippe Gythfeldt H, Lien T, Tekpli X, Silwal-Pandit L, Borgen E, Garred Ø, Skjerven H, Schlichting E, Lundgren S, Wist E, Naume B, Kristensen V, Børresen-Dale AL, Lingjaerde OC, Engebraaten O. von der Lippe Gythfeldt H, et al. Among authors: skjerven h. Int J Cancer. 2020 Nov 1;147(9):2515-2525. doi: 10.1002/ijc.33108. Epub 2020 Jun 18. Int J Cancer. 2020. PMID: 32488909 Clinical Trial.
LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer.
Sas-Chen A, Aure MR, Leibovich L, Carvalho S, Enuka Y, Körner C, Polycarpou-Schwarz M, Lavi S, Nevo N, Kuznetsov Y, Yuan J, Azuaje F; Oslo Breast Cancer Research Consortium (OSBREAC)SauerTorillGeislerJürgenHofvindSolveigBathenTone FBorgenElinEngebråtenOlavFodstadØysteinGarredØysteinGeitvikGry AarumKåresenRolfNaumeBjørnMælandsmoGunhild MariRussnesHege GSchlichtingEllenSørlieThereseLingjærdeOle ChristianSahlbergKristine KleiviSkjervenHelle KristineFritzmanBritt; Ulitsky I, Diederichs S, Wiemann S, Yakhini Z, Kristensen VN, Børresen-Dale AL, Yarden Y. Sas-Chen A, et al. EMBO Mol Med. 2016 Sep 1;8(9):1052-64. doi: 10.15252/emmm.201606198. Print 2016 Sep. EMBO Mol Med. 2016. PMID: 27485121 Free PMC article.
Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome.
Aure MR, Vitelli V, Jernström S, Kumar S, Krohn M, Due EU, Haukaas TH, Leivonen SK, Vollan HK, Lüders T, Rødland E, Vaske CJ, Zhao W, Møller EK, Nord S, Giskeødegård GF, Bathen TF, Caldas C, Tramm T, Alsner J, Overgaard J, Geisler J, Bukholm IR, Naume B, Schlichting E, Sauer T, Mills GB, Kåresen R, Mælandsmo GM, Lingjærde OC, Frigessi A, Kristensen VN, Børresen-Dale AL, Sahlberg KK; OSBREAC. Aure MR, et al. Breast Cancer Res. 2017 Mar 29;19(1):44. doi: 10.1186/s13058-017-0812-y. Breast Cancer Res. 2017. PMID: 28356166 Free PMC article.
The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer.
Silwal-Pandit L, Nord S, von der Lippe Gythfeldt H, Møller EK, Fleischer T, Rødland E, Krohn M, Borgen E, Garred Ø, Olsen T, Vu P, Skjerven H, Fangberget A, Holmen MM, Schlitchting E, Wille E, Nordberg Stokke M, Moen Vollan HK, Kristensen V, Langerød A, Lundgren S, Wist E, Naume B, Lingjærde OC, Børresen-Dale AL, Engebraaten O. Silwal-Pandit L, et al. Among authors: skjerven h. Clin Cancer Res. 2017 Aug 15;23(16):4662-4670. doi: 10.1158/1078-0432.CCR-17-0160. Epub 2017 May 9. Clin Cancer Res. 2017. PMID: 28487444 Clinical Trial.
DNA methylation at enhancers identifies distinct breast cancer lineages.
Fleischer T, Tekpli X, Mathelier A, Wang S, Nebdal D, Dhakal HP, Sahlberg KK, Schlichting E; Oslo Breast Cancer Research Consortium (OSBREAC); Børresen-Dale AL, Borgen E, Naume B, Eskeland R, Frigessi A, Tost J, Hurtado A, Kristensen VN. Fleischer T, et al. Nat Commun. 2017 Nov 9;8(1):1379. doi: 10.1038/s41467-017-00510-x. Nat Commun. 2017. PMID: 29123100 Free PMC article.
Breast cancer quantitative proteome and proteogenomic landscape.
Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF, Schlichting E, Naume B; Consortia Oslo Breast Cancer Research Consortium (OSBREAC); Luders T, Borgen E, Kristensen VN, Russnes HG, Lingjærde OC, Mills GB, Sahlberg KK, Børresen-Dale AL, Lehtiö J. Johansson HJ, et al. Nat Commun. 2019 Apr 8;10(1):1600. doi: 10.1038/s41467-019-09018-y. Nat Commun. 2019. PMID: 30962452 Free PMC article.
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment.
Tekpli X, Lien T, Røssevold AH, Nebdal D, Borgen E, Ohnstad HO, Kyte JA, Vallon-Christersson J, Fongaard M, Due EU, Svartdal LG, Sveli MAT, Garred Ø; OSBREAC; Frigessi A, Sahlberg KK, Sørlie T, Russnes HG, Naume B, Kristensen VN. Tekpli X, et al. Nat Commun. 2019 Dec 3;10(1):5499. doi: 10.1038/s41467-019-13329-5. Nat Commun. 2019. PMID: 31796750 Free PMC article.
The expression of the long NEAT1_2 isoform is associated with human epidermal growth factor receptor 2-positive breast cancers.
Knutsen E, Lellahi SM, Aure MR, Nord S, Fismen S, Larsen KB, Gabriel MT, Hedberg A, Bjørklund SS; Oslo Breast Cancer Research Consortium (OSBREAC); Bofin AM, Mælandsmo GM, Sørlie T, Mortensen ES, Perander M. Knutsen E, et al. Sci Rep. 2020 Jan 28;10(1):1277. doi: 10.1038/s41598-020-57759-4. Sci Rep. 2020. PMID: 31992741 Free PMC article.
108 results